Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Cash from Operations: 2018-2024

Historic Cash from Operations for Gossamer Bio (GOSS) over the last 7 years, with Dec 2024 value amounting to -$3.5 million.

  • Gossamer Bio's Cash from Operations fell 12.91% to -$36.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.4 million, marking a year-over-year decrease of 11128.42%. This contributed to the annual value of -$3.5 million for FY2024, which is 97.82% up from last year.
  • Latest data reveals that Gossamer Bio reported Cash from Operations of -$3.5 million as of FY2024, which was up 97.82% from -$159.2 million recorded in FY2023.
  • In the past 5 years, Gossamer Bio's Cash from Operations registered a high of -$3.5 million during FY2024, and its lowest value of -$188.9 million during FY2021.
  • Its 3-year average for Cash from Operations is -$116.6 million, with a median of -$159.2 million in 2023.
  • In the last 5 years, Gossamer Bio's Cash from Operations dropped by 21.77% in 2020 and then skyrocketed by 97.82% in 2024.
  • Yearly analysis of 5 years shows Gossamer Bio's Cash from Operations stood at -$176.4 million in 2020, then dropped by 7.10% to -$188.9 million in 2021, then rose by 0.98% to -$187.0 million in 2022, then climbed by 14.90% to -$159.2 million in 2023, then spiked by 97.82% to -$3.5 million in 2024.